How to Navigate Ecosystem Connect NEW Distinguished Investigators 
Global Conferences RLT Education RLT Components Sponsors Trial Stats
Global Conferences RLT Education RLT Components Sponsors Trial Stats 
How to NavigateNEW Ecosystem Connect Distinguished Investigators Global Conferences RLT Education RLT Components Sponsors Trial Stats Dictionary About Us Our Values
Contact XCancer
Luke Nordquist, MD, FACP, CEO
drluke@xcancer.comTony Romero, MS, CCRC, Director of Research
tromero@gucancer.comCopper Cu-64 TP3805 PET/CT in Imaging Patients With Urothelial Cancer Undergoing Surgery or Biopsy
Description:
This pilot clinical trial studies how well copper Cu-64 TP3805 positron emission tomography (PET)/computed tomography (CT) works in imaging patients with urothelial cancer undergoing surgery or biopsy. Radioactive tracers, such as copper Cu-64 TP3805, may bind to tumor cells. PET/CT imaging performed with copper Cu-64 TP3805 may be a better way to detect urothelial cancer.
Sponsor:
Unknown Organization
Phase:
Early Phase 1
Contacts:
Madhukar Thakur, PhD (PRINCIPAL_INVESTIGATOR)Government Study Link:
NCT03039413 - Click here to see study onClinicalTrials.gov
TP3805
Isotope(s):
COPPER-64
Radioisotope: Cu-64
Theranostic Role: PET Imaging
T1/2 (Half-Life): 12.7 Hours
Decay Mode: POSITRON β+, BETA, Electron Capture, GAMMA
Energy: 0.65 MeV, Gamma 511 keV
Range: max 2.5mm, mean 0.7mm
Decay Daughters: Ni64 (Stable), Zn64 (Stable)
Status: FDA Approval: DETECTNET®
Target(s):
- Vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide receptor 1 (VPAC1)
Ligand Class: Peptides
Inclusion
- Must have diagnosis of urothelial cancer
- Scheduled for extirpative surgery or biopsy of suspected metastatic lesion
Exclusion
- Must not have had an injection of a radioisotope 24 hours prior to exam
Share your feedback
Help us improve your experience